FDA CLEARS BIOSPHERE MEDICAL'S NEXT GENERATION EMBOCATH PLUS INFUSION MICROCATHETER

BioSphere Medical, Inc., a medical device company that pioneered the use of bioengineered microspheres to treat uterine fibroids, hypervascularized tumors and vascular malformations by a procedure called embolization, announced that the U.S. Food and Drug Administration has cleared for marketing in the United States BioSphere Medical's EmboCath Plus Infusion Microcatheter. EmboCath Plus is expected to begin shipping in the United States in September 2006.
Genetic Engineering News